• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Effects of GATA1 mutation types on megakaryocytic differentiation and development of leukemia

Research Project

Project/Area Number 21K07790
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 52050:Embryonic medicine and pediatrics-related
Research InstitutionHirosaki University

Principal Investigator

Terui Kiminori  弘前大学, 医学研究科, 教授 (00333740)

Co-Investigator(Kenkyū-buntansha) 土岐 力  弘前大学, 医学研究科, 講師 (50195731)
Project Period (FY) 2021-04-01 – 2024-03-31
Project Status Completed (Fiscal Year 2023)
Budget Amount *help
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2023: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2022: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2021: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Keywordsダウン症候群 / 一過性異常骨髄増殖症 / GATA1 / 血小板 / 巨核球 / 白血病 / 血小板数 / 急性骨髄性白血病
Outline of Research at the Start

ダウン症候群の新生児の約10%は一過性異常骨髄増殖症(TAM)という一過性の白血病を発症し、20~30%の症例は4歳までに真の白血病(AML)に進展する。どのような症例がAMLに進展するかについては十分解明されていない。TAMとAMLのほぼ全例でGATA1遺伝子の変異がみられるが、我々はGATA1変異の特定のタイプを持つ症例で血小板数が多く、AMLへの進展が少ない傾向にあることを見出した。本研究の目的は、患者検体や白血病細胞株を用いた解析を行い、TAMにおいてGATA1変異タイプにより血小板数やAMLへの進展率が異なる仕組みを明らかにし、新しいAMLの予防法・治療法の開発につなげることである。

Outline of Final Research Achievements

We performed this study to evaluate the effects of GATA1 mutation types on megakaryocytic differentiation and development of leukemia in infants with Down syndrome and TAM and obtained following results.
1. We found that overexpression of GATA1s protein upregulated the expression of megakaryocytic genes in an AML cell line of Down syndrome, CMK11-5, suggesting that the high expression of GATA1s protein may promote megakaryocytic differentiation.
2. We edited the GATA1 mutation of CMK11-5 cell line from premature termination codon (PTC) type to splicing error (SE) type and found that expression levels of megakaryocytic genes were higher in the SE type, suggesting the SE type of the GATA1 mutation may induce megakaryocytic differentiation more efficiently than the PTC type. Expression level of GATA1s protein was slightly higher in the SE type than the PTC type.

Academic Significance and Societal Importance of the Research Achievements

これまでの研究により、ダウン症のTAMにおいて、GATA1変異のタイプにより血小板数やAMLに進展する率が異なることは分かっていたが、その機序は不明であった。本研究により、GATA1変異のタイプにより巨核球分化に及ぼす影響が異なり、その影響はGATA1sタンパクの発現レベルの違いによることが示唆された。巨核球分化を促進するGATA1変異タイプはAMLに進展する率が低いことが予想され、今回の結果は過去に行われた臨床研究の結果と矛盾のない結果であった。GATA1変異解析により、AMLに進展する高危険群を正確に同定できるようになれば、AMLの早期発見・早期治療や、予防に応用できる可能性がある。

Report

(4 results)
  • 2023 Annual Research Report   Final Research Report ( PDF )
  • 2022 Research-status Report
  • 2021 Research-status Report
  • Research Products

    (14 results)

All 2024 2023 2022 2021

All Journal Article (9 results) (of which Int'l Joint Research: 1 results,  Peer Reviewed: 9 results,  Open Access: 4 results) Presentation (4 results) (of which Int'l Joint Research: 1 results,  Invited: 1 results) Book (1 results)

  • [Journal Article] Landscape of driver mutations and their clinical effects on Down syndrome-related myeloid neoplasms2024

    • Author(s)
      Sato Tomohiko、Yoshida Kenichi、...、Matsuo Hidemasa、...、Ito Etsuro
    • Journal Title

      Blood

      Volume: - Issue: 25 Pages: 2627-2643

    • DOI

      10.1182/blood.2023022247

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed / Int'l Joint Research
  • [Journal Article] Antileukemic effect of azacitidine, a DNA methyltransferase inhibitor, on cell lines of myeloid leukemia associated with Down syndrome2024

    • Author(s)
      Tanaka Tatsuhiko、Kudo Ko、Kanezaki Rika、Yuzawa Kentaro、Toki Tsutomu、Okuse Ryo、Kobayashi Akie、Sato Tomohiko、Kamio Takuya、Terui Kiminori、Ito Etsuro
    • Journal Title

      Experimental Hematology

      Volume: 132 Pages: 104179-104179

    • DOI

      10.1016/j.exphem.2024.104179

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Transient erythroblastopenia due to a GATA1 variant in an infant female2023

    • Author(s)
      Yamashita Motoi、Tomoda Takahiro、Mizuo Ami、Isoda Takeshi、Egawa Makiko、Yoshida Masayuki、Toki Tsutomu、Kudo Ko、Terui Kiminori、Ito Etsuro、Morio Tomohiro、Takagi Masatoshi
    • Journal Title

      Pediatric Blood & Cancer

      Volume: 71 Issue: 3

    • DOI

      10.1002/pbc.30834

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Mechanism of KIT gene regulation by GATA1 lacking the N-terminal domain in Down syndrome-related myeloid disorders2022

    • Author(s)
      Kanezaki Rika、Toki Tsutomu、Terui Kiminori、Sato Tomohiko、Kobayashi Akie、Kudo Ko、Kamio Takuya、Sasaki Shinya、Kawaguchi Koji、Watanabe Kenichiro、Ito Etsuro
    • Journal Title

      Scientific Reports

      Volume: 12 Issue: 1 Pages: 20587-20587

    • DOI

      10.1038/s41598-022-25046-z

    • Related Report
      2022 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Dyserythropoietic anaemia with an intronic GATA1 splicing mutation in patients suspected to have Diamond‐Blackfan anaemia2022

    • Author(s)
      Kobayashi Akie、Ohtaka Ryusei、Toki Tsutomu、Hara Junichi、Muramatsu Hideki、Kanezaki Rika、Takahashi Yuka、Sato Tomohiko、Kamio Takuya、Kudo Ko、Sasaki Shinya、Yoshida Taro、Utsugisawa Taiju、Kanno Hitoshi、Yoshida Kenichi、Nannya Yasuhito、Takahashi Yoshiyuki、Kojima Seiji、Miyano Satoru、Terui Kiminori、et al.
    • Journal Title

      eJHaem

      Volume: 3 Issue: 1 Pages: 163-167

    • DOI

      10.1002/jha2.374

    • Related Report
      2022 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] A phase III clinical trial evaluating efficacy and safety of minimal residual disease-based risk stratification for children with acute myeloid leukemia, incorporating a randomized study of gemtuzumab ozogamicin in combination with post-induction chemotherapy for non-low-risk patients (JPLSG-AML-20)2022

    • Author(s)
      Tomizawa Daisuke、Tsujimoto Shin-ichi、Tanaka Shiro、Matsubayashi Jun、Aoki Takahiro、Iwamoto Shotaro、Hasegawa Daisuke、Nagai Kozo、Nakashima Kentaro、Kawaguchi Koji、Deguchi Takao、Kiyokawa Nobutaka、Ohki Kentaro、Hiramatsu Hidefumi、Shiba Norio、Terui Kiminori、Saito Akiko Moriya、Kato Motohiro、Taga Takashi、et al.
    • Journal Title

      Japanese Journal of Clinical Oncology

      Volume: 52 Pages: 1225-1231

    • DOI

      10.1093/jjco/hyac105

    • Related Report
      2022 Research-status Report
    • Peer Reviewed
  • [Journal Article] A Case of Congenital Leukemia With MYB-GATA1 Fusion Gene in a Female Patient2021

    • Author(s)
      Ozono Shuichi、Yano Shoichiro、Oishi Saori、Mitsuo Miho、Nakagawa Shinichiro、Toki Tsutomu、Terui Kiminori、Ito Etsuro
    • Journal Title

      Journal of Pediatric Hematology/Oncology

      Volume: 44 Issue: 1 Pages: e250-e252

    • DOI

      10.1097/mph.0000000000002119

    • Related Report
      2021 Research-status Report
    • Peer Reviewed
  • [Journal Article] Predictive factors for the development of leukemia in patients with transient abnormal myelopoiesis and Down syndrome2021

    • Author(s)
      Yamato G, Deguchi T, Terui K, Toki T, Watanabe T, Imaizumi T, Hama A, Iwamoto S, Hasegawa D, Ueda T, Yokosuka T, Tanaka S, Yanagisawa R, Koh K, Saito AM, Horibe K, Hayashi Y, Adachi S, Mizutani S, Taga T, Ito E, Watanabe K, Muramatsu H.
    • Journal Title

      Leukemia.

      Volume: 35 Issue: 5 Pages: 1480-1484

    • DOI

      10.1038/s41375-021-01171-y

    • Related Report
      2021 Research-status Report
    • Peer Reviewed
  • [Journal Article] Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of Down syndrome2021

    • Author(s)
      Taga Takashi, Terui Kiminori、Toki Tsutomu、Ito Etsuro、et al.
    • Journal Title

      Leukemia

      Volume: - Issue: 9 Pages: 2508-2516

    • DOI

      10.1038/s41375-021-01157-w

    • NAID

      120006988564

    • Related Report
      2021 Research-status Report
    • Peer Reviewed
  • [Presentation] Clinical characteristics of infants with transient abnormal myelopoiesis and two GATA1 mutations: A report from the JPLSG TAM-10 study2023

    • Author(s)
      Kana Soma, Tomohiko Sato, Tsutomu Toki, Rika Kanezaki, Ko Kudo, Genki Yamato, Hideki Muramatsu, Kenichiro Watanabe, Etsuro Ito, Kiminori Terui
    • Organizer
      第65回日本小児血液・がん学会学術集会
    • Related Report
      2023 Annual Research Report
  • [Presentation] Cytokine profiling in 128 patients with transient abnormal myelopoiesis: JPLSG TAM-10 study2023

    • Author(s)
      Genki Yamato, Hideki Muramatsu, Akira Shimada, Takahiro Imaizumi, Hiroyuki Tsukagoshi, Norio Shiba, Kiminori Terui, Etsuro Ito, Kenichiro Watanabe, Yasuhide Hayashi
    • Organizer
      第65回日本小児血液・がん学会学術集会
    • Related Report
      2023 Annual Research Report
  • [Presentation] Down症候群関連骨髄性白血病における新規予後因子の探索2022

    • Author(s)
      照井君典
    • Organizer
      第64回日本小児血液・がん学会学術集会
    • Related Report
      2022 Research-status Report
    • Invited
  • [Presentation] Cytokine Analysis in 154 Patients with transient abnormal myelopoiesis: JCCG JPLSG TAM-10 clinical study2021

    • Author(s)
      1.Yamato G, Park MJ, Shimada A, Shiba N, Yamada Y, Terui K, Ito E, Muramatsu H, Watanabe K and Hayashi Y
    • Organizer
      American Society of Hematology 63rd Annual Meeting
    • Related Report
      2021 Research-status Report
    • Int'l Joint Research
  • [Book] 小児白血病・リンパ腫―Strategy & Practice2021

    • Author(s)
      滝田順子
    • Total Pages
      344
    • Publisher
      中山書店
    • ISBN
      9784521749211
    • Related Report
      2021 Research-status Report

URL: 

Published: 2021-04-28   Modified: 2025-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi